Sweta Jonnalagadda, MD
Medical Oncology · Fort Myers, FLNPI 1851667109
Payments from drug & device makers
Across 67 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$214
- AstraZeneca$123
- Bayer$118
- E.r. Squibb & Sons, L.L.C.$106
- Seagen Inc.$106
- Daiichi Sankyo Inc.$77
- plus $743 from 21 others
What the payments were for
- Food & beverage$1,487100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $214 |
| AstraZeneca(2 entities) | 6 | $123 |
| Bayer | 5 | $118 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Seagen Inc. | 5 | $106 |
| Daiichi Sankyo Inc. | 3 | $77 |
| Merck | 3 | $73 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Astellas Pharma US Inc | 3 | $66 |
| AbbVie | 2 | $60 |
| Sanofi | 2 | $54 |
| Lilly USA, LLC | 2 | $50 |
| Eisai Inc. | 2 | $44 |
| EMD Serono, Inc. | 2 | $38 |
| Mirati Therapeutics, Inc. | 2 | $34 |
| Immunogen, Inc. | 1 | $29 |
| Incyte Corporation | 1 | $28 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$1,487 in reported general payments places this provider in the 15th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 14 | $157 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Fort Myers
- Lowell HartFort Myers$10.1M
- James ReevesFort Myers$7.1M
- Syed ZafarFort Myers$4M
- Raymond EsperFort Myers$3.2M
- William HarwinFort Myers$2.8M
- Zeynep ErogluTampa$30.9M
- Manish PatelSarasota$29.7M
- Jad ChahoudTampa$21.8M
- Maen HusseinTavares$18.4M
- Patrick HwuTampa$18M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.